Unfortunately, the disease burden of NCDs is growing worldwide. Globally, NCDs is expected to increase by 17% in the next 10 years, and in the African region by 27%. According to WHO, more than 14 million people between the ages of 30 and 70 die each year of NCDs – of which 85% live in low- and middle income countries.
Sukinn has given high importance to approving generically available sources of essential NCD products, such as glucose test strips (diabetes), doxorubicin (cancer treatment), atenolol (cardiovascular diseases) and salbutamol (chronic respiratory diseases), amongest others.